Personalized treatment for early-stage nasal lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a treatment plan for early-stage NK/T-cell lymphoma of the nose or throat. The treatment is adjusted based on how well the disease responds, aiming to be more effective and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with early-stage NK/T-cell lymphoma in the nose, sinuses, or mouth area.
- You have not had chemotherapy, radiation, or other lymphoma treatments before.
- You are generally able to care for yourself (performance status 0-2) and have adequate organ function.
- You do not have HIV, active hepatitis B or C, or other serious infections or conditions that would make the treatment unsafe.
- You are not pregnant or breastfeeding, and you are willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
This study tests whether patients with a specific type of blood cancer (NK/T-cell lymphoma) in the nose or sinuses who have responded well to chemotherapy can be safely treated with reduced radiation doses instead of standard high-dose radiation. The goal is to reduce side effects while maintaining effective treatment.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
This trial tests whether combining chemotherapy with radiation therapy can work well for people with early-stage NK/T-cell lymphoma that started in the nose or throat. It aims to find a more effective treatment approach with fewer side effects.
Hear when a new Natural Killer/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.